Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?

  title={Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?},
  author={Beatriz Cabanillas and Cezmi A. Akdis and Natalija Novak},
The COVID-19 vaccine developed by Pfizer and BioNTech was approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) on December 2nd 2020.1 MHRA is therefore the first regulator agency in the world to approve a vaccine to prevent coronavirus disease (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus that is responsible for a global pandemic. 
Cutaneous and Allergic reactions due to COVID‐19 vaccinations: A review
The pandemic caused by the novel coronavirus disease 2019 (COVID‐19) has had an unprecedented impact on the overall health and the global economy. Vaccination is currently the most dependable
Allergic reactions to COVID‐19 ‐vaccinations – unveiling the secret(s)
This issue of Allergy features articles with current information on allergy‐related questions regarding COVID‐19 vaccination.
COVID‐19 vaccines and the role of other potential allergenic components different from PEG. A reply to: “Other excipients than PEG might cause serious hypersensitivity reactions in COVID‐19 vaccines”
To the Editor, Thank you for the correspondence of Borgsteede et al “Other excipients than PEG might cause serious hypersensitivity reactions in COVID19 vaccines.”1 We agree with the authors and
A Bullous Eruption following the Pfizer‐BioNTech COVID‐19 vaccination
An ongoing multinational randomised controlled trial assessing the safety of the Pfizer-BioNTech COVID-19 vaccine reported few localized cutaneous reactions at the injection site, but no significant adverse cutaneous allergic reactions.
Practical handling of allergic reactions to COVID-19 vaccines
Recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts, and allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination.
Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?
The vaccination campaign against the Severe acute respiratory syndrome coronavirus 2 (Sars-Cov-2) started on 8 December 2020 in UK, after the approval of BNT162b2 by the Healthcare products
COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches
  • W. Laisuan
  • Medicine, Biology
    Frontiers in Allergy
  • 2021
Skin testing, using the basophil activation test, has been used to clarify the mechanism of the anaphylaxis and provide safety information for the next injection and suggested approaches for patients who experienced an immediate severe allergic reaction to the first dose of a COVID-19 vaccine.
Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia
An updated review of the last scientific findings that can explain the rare side effects that the vaccines for COVID-19 can produce is provided.
Allergy to COVID-19 vaccines: A current update


Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Immediate‐type hypersensitivity to polyethylene glycols: a review
  • E. Wenande, L. Garvey
  • Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2016
This first comprehensive review provides practical information for allergists and other healthcare professionals by describing the clinical picture of 37 reported cases of P EG hypersensitivity since 1977, summarizing instances where PEG hypersensitivity should be considered and proposing an algorithm for diagnostic management.
Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized.
Polyethylene glycol as a cause of anaphylaxis
Potential life-threatening hypersensitivity reactions to hidden molecules like macrogol may be underdiagnosed and the awareness regarding the allergenic potential of PEG should be raised and a proper product labelling is crucial to prevent PEG mediated hypersensitivity.
Polyethylene Glycol Induced Systemic Allergic Reactions (Anaphylaxis).
A case of anaphylaxis caused by macrogol 3350 after injection of a corticosteroid
Macrogols are polymers of ethylene glycol, and are widely used in food and food packaging, and also in cosmetics and pharmaceutical preparations as solvents, softening agents, and lubricants.
Anti-PEG IgE In Anaphylaxis Associated with Polyethylene Glycol.